Related Experiment Video
Updated: Apr 10, 2026

Identification of the Source of Secreted Proteins in the Kidney by Brefeldin A Injection
Published on: November 10, 2021
TGF-Beta Blockade Increases Renal Inflammation Caused by the C-Terminal Module of the CCN2
Raquel Rodrigues-Díez1, Sandra Rayego-Mateos1, Macarena Orejudo1
1Cellular Biology in Renal Diseases Laboratory, School of Medicine, Universidad Autónoma Madrid, 28040 Madrid, Spain.
Abstract:
The CCN family member 2 (CCN2, also known as connective tissue growth factor) may behave as a risk biomarker and a potential therapeutic target for renal disease. CCN2 participates in the regulation of inflammation and fibrosis. TGF-β is considered the main fibrogenic cytokine; however, in some pathological settings TGF-β also has anti-inflammatory properties. CCN2 has been proposed as a downstream profibrotic mediator of TGF-β, but data on TGF-β role in CCN2 actions are scarce. Our aim was to evaluate the effect of TGF-β blockade in CCN2-mediated experimental renal damage. Systemic administration of the C-terminal module of CCN2 to mice caused sustained renal inflammation. In these mice, TGF-β blockade, using an anti-TGF-β neutralizing antibody, significantly increased renal expression of the NGAL (a kidney injury biomarker), kidney infiltration by monocytes/macrophages, and upregulation of MCP-1 expression. The anti-inflammatory effect of TGF-β seems to be mediated by a dysregulation of the systemic Treg immune response, shown by decreased levels of circulating CD4(+)/Foxp3(+)Treg cells. Our experimental data support the idea that TGF-β exerts anti-inflammatory actions in the kidney and suggest that it is not an optimal therapeutic target.
Insights
Connective tissue growth factor (CCN2) can worsen kidney disease. Blocking TGF-β, thought to promote fibrosis, actually worsened CCN2-induced kidney inflammation and injury in mice.
Area of Science:
- Nephrology
- Immunology
- Cell Biology
Background:
- Connective tissue growth factor (CCN2) is implicated in renal disease pathogenesis, potentially mediating inflammation and fibrosis.
- Transforming growth factor-beta (TGF-β) is a key fibrogenic cytokine, but its role in CCN2-driven pathology and its own anti-inflammatory properties remain incompletely understood.
Purpose of the Study:
- To investigate the impact of TGF-β blockade on experimental renal damage induced by CCN2.
- To elucidate the mechanisms underlying TGF-β's role in CCN2-mediated kidney injury and inflammation.
Main Methods:
- Systemic administration of the CCN2 C-terminal module to induce renal inflammation in mice.
- Treatment with an anti-TGF-β neutralizing antibody to block TGF-β activity.
- Assessment of renal NGAL expression, monocyte/macrophage infiltration, MCP-1 levels, and circulating Treg cell populations (CD4+/Foxp3+).
Main Results:
- CCN2 administration led to sustained renal inflammation.
- TGF-β blockade significantly exacerbated kidney injury, indicated by increased NGAL expression and monocyte/macrophage infiltration.
- Blocking TGF-β also upregulated MCP-1 expression and decreased circulating regulatory T cells (Tregs), suggesting immune dysregulation.
Conclusions:
- The study demonstrates that TGF-β exerts protective anti-inflammatory effects in the kidney during CCN2-induced damage.
- TGF-β blockade is not an optimal therapeutic strategy for this model of renal injury.
- These findings highlight the complex role of TGF-β in kidney disease and suggest caution in targeting it therapeutically.
Related Concept Videos
Antihypertensive Drugs: Action of β1 Blockers
GPCRs Regulate Adenylyl Cylase Activity
Acute Kidney Injury II: Pathophysiology
Antihypertensive Drugs: Angiotensin II Receptor Blockers
Intracellular Signaling Affects Focal Adhesions
Some...
Antihypertensive Drugs: Direct Renin Inhibitors

